These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 28724618)
1. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618 [TBL] [Abstract][Full Text] [Related]
2. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Patel L; Bernard LM; Elder GJ Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. Spoendlin J; Paik JM; Tsacogianis T; Kim SC; Schneeweiss S; Desai RJ JAMA Intern Med; 2019 Jun; 179(6):741-749. PubMed ID: 31058913 [TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467 [TBL] [Abstract][Full Text] [Related]
5. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis. Prajapati VA; Galani VJ; Shah PR Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148 [TBL] [Abstract][Full Text] [Related]
6. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). Pergola PE; Rosenbaum DP; Yang Y; Chertow GM J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811 [TBL] [Abstract][Full Text] [Related]
7. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Covic AC; Sprague SM; Rastogi A; Ketteler M; Walpen S; Perrin A; Floege J Nephron; 2020; 144(9):428-439. PubMed ID: 32585670 [TBL] [Abstract][Full Text] [Related]
8. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost-efficacy of phosphate binders in hemodialysis. Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491 [TBL] [Abstract][Full Text] [Related]
10. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Tonelli M; Wiebe N; Culleton B; Lee H; Klarenbach S; Shrive F; Manns B; Nephrol Dial Transplant; 2007 Oct; 22(10):2856-66. PubMed ID: 17906326 [TBL] [Abstract][Full Text] [Related]
11. Design and baseline characteristics of the LANDMARK study. Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T; Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619 [TBL] [Abstract][Full Text] [Related]
12. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE; Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079 [TBL] [Abstract][Full Text] [Related]
13. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial. Ko SM; Zhang C; Chen Z; D'Marco L; Bellasi A; Stillman AE; Block G; Raggi P J Nephrol; 2016 Oct; 29(5):683-90. PubMed ID: 27102490 [TBL] [Abstract][Full Text] [Related]
15. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Rastogi A Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730 [TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients. Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903 [TBL] [Abstract][Full Text] [Related]
17. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Di Iorio B; Bellasi A; Russo D; Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819 [TBL] [Abstract][Full Text] [Related]
18. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use. Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640 [TBL] [Abstract][Full Text] [Related]
19. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017 [TBL] [Abstract][Full Text] [Related]
20. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]